Fingolimod in children with Rett syndrome: the FINGORETT study

• Published in: Orphanet journal of rare diseases Vol. 16; no. 1; p. 19
• Main Authors: Naegelin, Yvonne, Kuhle, Jens, Schädelin, Sabine, Datta, Alexandre N, Magon, Stefano, Amann, Michael, Barro, Christian, Ramelli, Gian Paolo, Heesom, Kate, Barde, Yves-Alain, Weber, Peter, Kappos, Ludwig
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 06.01.2021; BioMed Central; BMC
• Subjects: Adverse events; Apraxia; BDNF; Blood; Brain; Brain-derived neurotrophic factor; Cerebrospinal fluid; Children; Clinical trials; Cognitive ability; Dosage and administration; Drug therapy; Enzymes; Fingolimod; General anesthesia; Magnetic resonance imaging; Mass spectrometry; MeCP2 protein; Medical research; Methyl-CpG binding protein; Mutation; Neurodevelopmental disorders; Neuroimaging; Patient outcomes; Pediatric research; Pediatrics; Peptides; Rare diseases; Respiration; Rett syndrome; Scientific imaging; Substantia grisea; Switzerland; Fingolimod; BDNF; Rett syndrome
• ISSN: 1750-1172; 1750-1172
• DOI: 10.1186/s13023-020-01655-7

Rett syndrome (RS) is a severe neurodevelopmental disorder for which there is no approved therapy. This study aimed to assess safety and efficacy of oral fingolimod in children with RS using a pre-post and case-control design. At the University of Basel Children's Hospital, Basel, Switzerland, children with RS were included if they were older than 6 years and met the established diagnostic criteria of RS, including a positive MeCP2 mutation. Participants were observed 6 months before and after treatment and received 12 months of fingolimod treatment. Serum samples of 50 children without RS served as reference for brain-derived neurotrophic factor (BDNF) measurements. Primary outcome measures were safety and efficacy, the latter measured by change in levels of BDNF in serum/CSF (cerebrospinal fluid) and change in deep gray matter volumes measured by magnetic resonance imaging (MRI). Secondary outcome measure was efficacy measured by change in clinical scores [Vineland Adaptive Behaviour Scale (VABS), Rett Severity Scale (RSSS) and Hand Apraxia Scale (HAS)]. Six children with RS (all girls, mean and SD age 11.3 ± 3.1 years) were included. Serum samples of 50 children without RS (25 females, mean and SD age 13.5 ± 3.9 years) served as reference for BDNF measurements. No serious adverse events occurred. Primary and secondary outcome measures were not met. CSF BDNF levels were associated with all clinical scores: RSSS (estimate - 0.04, mult.effect 0.96, CI [0.94; 0.98], p = 0.03), HAS (estimate - 0.09, mult.effect 0.91, CI [0.89; 0.94], p <  0.01) and VABS (communication: estimate 0.03, mult.effect 1.03, CI [1.02; 1.04], p < 0.01/daily living: estimate 0.03, mult.effect 1.03, CI [1.02; 1.04], p < 0.01/social skills: estimate 0.07, mult.effect 1.08, CI [1.05; 1.11], p < 0.01/motoric skills: estimate 0.04, mult.effect 1.04, CI [1.03; 1.06], p = 0.02). In children with RS, treatment with fingolimod was safe. The study did not provide supportive evidence for an effect of fingolimod on clinical, laboratory, and imaging measures. CSF BDNF levels were associated with clinical scores, indicating a need to further evaluate its potential as a biomarker for RS. This finding should be further validated in independent patient groups. Clinical Trials.gov NCT02061137, registered on August 27th 2013, https://clinicaltrials.gov/ct2/show/study/NCT02061137 .